Relmada Therapeutics, Inc.RLMD

Relmada Therapeutics, Inc. (RLMD) has reported a net loss of $19.1 million for the quarter ending March 31, 2026, a stark reminder of the financial challenges faced by clinical-stage biotechnology companies. The company’s operating income (or rather, loss) stands at $-19.5 million, reflecting the significant costs associated with research and development in the biotech sector. Despite these losses, Relmada has managed to maintain a robust stockholders’ equity of $218.7 million, indicating strong financial backing and investor confidence.

Relmada is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. The company’s pipeline includes innovative therapies such as NDV-01, a novel sustained-release intravesical therapy for patients with non-muscle invasive bladder cancer (NMIBC). Relmada’s strategic moves, including the recent appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer, underscore its commitment to advancing its pipeline and building the commercial and strategic capabilities needed for success.

For the quarter ending March 31, 2026, Relmada reported research and development expenses of $8.1 million, highlighting the significant investment required to advance its clinical programs. The company’s balance sheet shows $9.8 million in cash and cash equivalents and $224.2 million in short-term investments, providing a financial cushion for ongoing operations. However, the net cash used in operating activities was $-15.1 million, indicating a substantial cash burn rate. Diluted earnings per share for the quarter were $-0.22, with a weighted average number of shares outstanding of 86.6 million. (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1553643/000121390026082007/ea0299449-8k_relmada.htm)

Relmada Therapeutics is set to report its second-quarter 2026 financial results on Thursday, August 6, 2026. The company’s inclusion in the Russell 2000® and Russell 3000® Indexes is a significant milestone, reflecting its growing market presence and investor interest. For those looking to examine deeper into Relmada’s financials and market performance, the Investors section of the company’s website at https://www.relmada.com/investors/ir-calendar offers a wealth of information, including webcast replays and financial reports. (source: Official product/news rail, https://www.relmada.com/for-investors/news/detail/343/relmada-therapeutics-to-report-second-quarter-2026)